AIMS: We determined whether the start of selective serotonin reuptake inhibitors (SSRI) in levodopa users was followed by a faster increase of antiparkinsonian drug treatment. METHODS: Selected were all levodopa users of 55 years and older from the PHARMO prescription database. The rate of increase of antiparkinsonian drug treatment was compared using Cox's proportional hazard model for starters of SSRI (n = 15) with starters of tricyclic antidepressants (TCA) (n = 31) and with patients not using antidepressants (n = 304), and was adjusted for age, gender, and duration of levodopa use. RESULTS: The hazard ratio for the SSRI group compared with the TCA group was 4.2 (95% confidence interval 1.4, 12.6) and compared with the second control group was 2.7 (1.2, 5.2). CONCLUSIONS: The start of SSRI therapy in levodopa users is followed by a faster increase of antiparkinsonian drug treatment.
AIMS: We determined whether the start of selective serotonin reuptake inhibitors (SSRI) in levodopa users was followed by a faster increase of antiparkinsonian drug treatment. METHODS: Selected were all levodopa users of 55 years and older from the PHARMO prescription database. The rate of increase of antiparkinsonian drug treatment was compared using Cox's proportional hazard model for starters of SSRI (n = 15) with starters of tricyclic antidepressants (TCA) (n = 31) and with patients not using antidepressants (n = 304), and was adjusted for age, gender, and duration of levodopa use. RESULTS: The hazard ratio for the SSRI group compared with the TCA group was 4.2 (95% confidence interval 1.4, 12.6) and compared with the second control group was 2.7 (1.2, 5.2). CONCLUSIONS: The start of SSRI therapy in levodopa users is followed by a faster increase of antiparkinsonian drug treatment.
Authors: R Ceravolo; A Nuti; A Piccinni; G Dell'Agnello; G Bellini; G Gambaccini; L Dell'Osso; L Murri; U Bonuccelli Journal: Neurology Date: 2000-10-24 Impact factor: 9.910
Authors: T Klaassen; F R Verhey; G H Sneijders; N Rozendaal; H C de Vet; H M van Praag Journal: J Neuropsychiatry Clin Neurosci Date: 1995 Impact factor: 2.198
Authors: Maurits E L Arbouw; Kris L L Movig; Cees Neef; Henk-Jan Guchelaar; Toine C G Egberts Journal: Eur J Clin Pharmacol Date: 2007-01-03 Impact factor: 2.953
Authors: Daniel Weintraub; Donna Taraborelli; Knashawn H Morales; John E Duda; Ira R Katz; Matthew B Stern Journal: J Neuropsychiatry Clin Neurosci Date: 2006 Impact factor: 2.198
Authors: Daniel Weintraub; Knashawn H Morales; Paul J Moberg; Warren B Bilker; Catherine Balderston; John E Duda; Ira R Katz; Matthew B Stern Journal: Mov Disord Date: 2005-09 Impact factor: 10.338